SCO-101治疗转移性结直肠癌患者的II期临床试验已开始

2019-10-05 Allan MedSci原创

Scandion Oncology制药公司近日宣布，该公司已向丹麦药品管理局提交了申请，以期允许SCO-101治疗转移性结直肠癌患者的II期临床研究，该研究将在丹麦的医院进行。

Scandion Oncology制药公司近日宣布，该公司已向丹麦药品管理局提交了申请，以期允许SCO-101治疗转移性结直肠癌患者的II期临床研究，该研究将在丹麦的医院进行。这项II期临床研究将分为两个部分进行，第一部包括12-15名患者，以证明SCO-101与化学疗法（FOLFIRI）结合使用时的安全性和耐受性。预计首批数据将于2020年第二季度发布，最终研究报告将于2021年上半年发布。

转移性结直肠癌（mCRC）患者大多不能治愈，但转移仅限于肝和/或肺、局部复发或局限性腹腔内病变的mCRC患者有手术治愈的可能。对其他mCRC患者采取姑息治疗，一般为全身化疗。

原始出处：

http://www.firstwordpharma.com/node/1671790#axzz61Rlned4y

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1931483, encodeId=e06d193148393, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Mar 15 11:48:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088769, encodeId=759d2088e6915, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jan 16 07:48:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652943, encodeId=fa09165294352, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Dec 10 16:48:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386545, encodeId=8eb613865450c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453309, encodeId=26551453309dc, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524740, encodeId=38831524e407b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373559, encodeId=822e3e355947, content=期待有好的结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sat Oct 05 20:22:51 CST 2019, time=2019-10-05, status=1, ipAttribution=)]
2020-03-15 kksonne

#II期临床试验#

32 0
[GetPortalCommentsPageByObjectIdResponse(id=1931483, encodeId=e06d193148393, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Mar 15 11:48:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088769, encodeId=759d2088e6915, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jan 16 07:48:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652943, encodeId=fa09165294352, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Dec 10 16:48:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386545, encodeId=8eb613865450c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453309, encodeId=26551453309dc, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524740, encodeId=38831524e407b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373559, encodeId=822e3e355947, content=期待有好的结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sat Oct 05 20:22:51 CST 2019, time=2019-10-05, status=1, ipAttribution=)]
2020-01-16 839640778

#I期临床试验#

30 0
[GetPortalCommentsPageByObjectIdResponse(id=1931483, encodeId=e06d193148393, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Mar 15 11:48:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088769, encodeId=759d2088e6915, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jan 16 07:48:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652943, encodeId=fa09165294352, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Dec 10 16:48:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386545, encodeId=8eb613865450c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453309, encodeId=26551453309dc, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524740, encodeId=38831524e407b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373559, encodeId=822e3e355947, content=期待有好的结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sat Oct 05 20:22:51 CST 2019, time=2019-10-05, status=1, ipAttribution=)]
2019-12-10 医生2402

#I期临床#

24 0
[GetPortalCommentsPageByObjectIdResponse(id=1931483, encodeId=e06d193148393, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Mar 15 11:48:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088769, encodeId=759d2088e6915, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jan 16 07:48:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652943, encodeId=fa09165294352, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Dec 10 16:48:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386545, encodeId=8eb613865450c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453309, encodeId=26551453309dc, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524740, encodeId=38831524e407b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373559, encodeId=822e3e355947, content=期待有好的结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sat Oct 05 20:22:51 CST 2019, time=2019-10-05, status=1, ipAttribution=)]
2019-10-07 1249842em09(暂无昵称)

#转移性#

32 0
[GetPortalCommentsPageByObjectIdResponse(id=1931483, encodeId=e06d193148393, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Mar 15 11:48:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088769, encodeId=759d2088e6915, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jan 16 07:48:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652943, encodeId=fa09165294352, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Dec 10 16:48:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386545, encodeId=8eb613865450c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453309, encodeId=26551453309dc, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524740, encodeId=38831524e407b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373559, encodeId=822e3e355947, content=期待有好的结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sat Oct 05 20:22:51 CST 2019, time=2019-10-05, status=1, ipAttribution=)]
2019-10-07 crystal0564

#结直肠#

28 0
[GetPortalCommentsPageByObjectIdResponse(id=1931483, encodeId=e06d193148393, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Mar 15 11:48:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088769, encodeId=759d2088e6915, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jan 16 07:48:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652943, encodeId=fa09165294352, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Dec 10 16:48:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386545, encodeId=8eb613865450c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453309, encodeId=26551453309dc, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524740, encodeId=38831524e407b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373559, encodeId=822e3e355947, content=期待有好的结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sat Oct 05 20:22:51 CST 2019, time=2019-10-05, status=1, ipAttribution=)]
2019-10-07 guihongzh

#II期临床#

25 0
[GetPortalCommentsPageByObjectIdResponse(id=1931483, encodeId=e06d193148393, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Mar 15 11:48:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088769, encodeId=759d2088e6915, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Jan 16 07:48:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652943, encodeId=fa09165294352, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Dec 10 16:48:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386545, encodeId=8eb613865450c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453309, encodeId=26551453309dc, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524740, encodeId=38831524e407b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon Oct 07 07:48:00 CST 2019, time=2019-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373559, encodeId=822e3e355947, content=期待有好的结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Sat Oct 05 20:22:51 CST 2019, time=2019-10-05, status=1, ipAttribution=)]
2019-10-05 njwbhuang

期待有好的结果。

75 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

消化

SCO-101治疗转移性结直肠癌患者的II期临床试验已开始

相关资讯

科室

工具

服务